Giacomo Salvadore

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 35:1415-22. 2010
  2. pmc Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuroimage 54:2643-51. 2011
  3. pmc Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Biol Psychiatry 66:804-7. 2009
  4. pmc Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 65:289-95. 2009
  5. pmc Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression
    Brian R Cornwell
    Section on Neurobiology of Fear and Anxiety, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Psychiatry 72:555-61. 2012
  6. pmc Early intervention in bipolar disorder, part II: therapeutics
    Giacomo Salvadore
    Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Early Interv Psychiatry 2:136-46. 2008
  7. pmc An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression
    Giacomo Salvadore
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 15:1063-72. 2012
  8. pmc Abnormal hippocampal functioning and impaired spatial navigation in depressed individuals: evidence from whole-head magnetoencephalography
    Brian R Cornwell
    Mood and Anxiety Disorders Program, NIMH, 15K North Dr, MSC 2670, Bethesda, MD 20892, USA
    Am J Psychiatry 167:836-44. 2010
  9. pmc A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    Nancy Diazgranados
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arch Gen Psychiatry 67:793-802. 2010
  10. pmc Ketamine and the next generation of antidepressants with a rapid onset of action
    Rodrigo Machado-Vieira
    Experimental Therapeutics Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Pharmacol Ther 123:143-50. 2009

Collaborators

Detail Information

Publications19

  1. pmc Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 35:1415-22. 2010
    ..73, p=0.0021, FDR <0.05).These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context...
  2. pmc Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuroimage 54:2643-51. 2011
    ..Consistent with other neuroimaging and post-mortem neuropathological studies of MDD, we also found evidence of decreased white matter in patients with dMDD and rMDD...
  3. pmc Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Biol Psychiatry 66:804-7. 2009
    ..We tested the hypothesis that this SNP would modulate gray matter (GM) volume in the limbic-cortical-striatal-pallidal-thalamic circuitry that plays major roles in mood regulation...
  4. pmc Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 65:289-95. 2009
    ..We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation observed in healthy subjects...
  5. pmc Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression
    Brian R Cornwell
    Section on Neurobiology of Fear and Anxiety, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Psychiatry 72:555-61. 2012
    ..Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine...
  6. pmc Early intervention in bipolar disorder, part II: therapeutics
    Giacomo Salvadore
    Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Early Interv Psychiatry 2:136-46. 2008
    ..We also discuss their potential use as early intervention strategies for improving symptoms and functioning in patients in the earliest stages of BPD, as well as high-risk individuals...
  7. pmc An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression
    Giacomo Salvadore
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 15:1063-72. 2012
    ....
  8. pmc Abnormal hippocampal functioning and impaired spatial navigation in depressed individuals: evidence from whole-head magnetoencephalography
    Brian R Cornwell
    Mood and Anxiety Disorders Program, NIMH, 15K North Dr, MSC 2670, Bethesda, MD 20892, USA
    Am J Psychiatry 167:836-44. 2010
    ..The authors aimed to link spatial navigation deficits previously documented in depressed patients to abnormal hippocampal functioning using a virtual reality navigation task...
  9. pmc A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    Nancy Diazgranados
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arch Gen Psychiatry 67:793-802. 2010
    ..Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health...
  10. pmc Ketamine and the next generation of antidepressants with a rapid onset of action
    Rodrigo Machado-Vieira
    Experimental Therapeutics Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Pharmacol Ther 123:143-50. 2009
    ..Overall, understanding the molecular basis of this work will likely lead to the ultimate development of improved therapeutics for MDD...
  11. pmc Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, Maryland, 20892 1285, USA
    Prog Neuropsychopharmacol Biol Psychiatry 34:819-21. 2010
    ..Overall, our findings suggest a novel mechanism in the pathophysiology of BPD...
  12. pmc Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 15:1595-611. 2009
    ..This paper reviews the currently available knowledge regarding the role of the glutamatergic system in the etiopathogenesis of mood disorders and putative glutamate modulators...
  13. pmc Glutamatergic modulators: the future of treating mood disorders?
    Carlos Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Harv Rev Psychiatry 18:293-303. 2010
    ..Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder...
  14. pmc The neurobiology of the switch process in bipolar disorder: a review
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1488-501. 2010
    ..In this review, we summarize the clinical evidence regarding somatic interventions associated with switching, with a particular focus on the biologic underpinnings presumably involved in the switch process...
  15. pmc New therapeutic targets for mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    ScientificWorldJournal 10:713-26. 2010
    ....
  16. pmc Early intervention in bipolar disorder, part I: clinical and imaging findings
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    Early Interv Psychiatry 2:122-35. 2008
    ..A companion paper discusses the cellular and molecular mechanisms of action of agents with neurotrophic and neuroplastic properties, with a particular emphasis on lithium and valproate...
  17. pmc Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, MD 20892 1282, USA
    J Clin Psychiatry 69:946-58. 2008
    ..This article reviews the published data related to different aspects of rapid improvement of depressive symptoms...
  18. pmc Effects of lithium on oxidative stress parameters in healthy subjects
    Rushaniya Khairova
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Med Rep 5:680-2. 2012
    ..Overall, the present findings indicate a potential role for the antioxidant effects of lithium in healthy subjects, supporting its neuroprotective profile in bipolar disorder (BD) and, possibly, in neurodegenerative processes...
  19. pmc Valproate activates the Notch3/c-FLIP signaling cascade: a strategy to attenuate white matter hyperintensities in bipolar disorder in late life?
    Peixiong Yuan
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 11:256-69. 2009
    ....